Devonian Health Group (GSD) Q3 2024 earnings summary

Executive summary

• Third quarter marked by a breakout performance, with significant revenue growth and operational progress in both pharmaceutical and cosmeceutical segments.

• Altius subsidiary drove revenue surge through the successful launch of DEXLANSOPRAZOLE, the only authorized generic for GERD in Canada.

• Preparations advanced for phase II/III clinical study of Thykamine for pediatric atopic dermatitis.

• Leadership changes included appointing the founder as Chairman and COO to integrate research and production scaling.

Financial highlights

• Third quarter distribution revenue reached $5.13 million, up 1,162% year over year, driven by DEXLANSOPRAZOLE launch.

• Net loss for the quarter was $0.374 million ($0.002 per share), improved from $1.5 million ($0.01 per share) year over year.

• Nine-month year-to-date revenue was $8.68 million, up 583% year over year; net loss was $2.306 million ($0.02 per share), improved from $3.736 million ($0.03 per share) last year.

• Cash at April 30, 2024, was $3.5 million, with debt of $2.16 million, compared to $5.1 million cash and $3.6 million debt at the year's start.

Outlook and guidance

• Continued focus on advancing Thykamine clinical development and leveraging regulatory pathways for botanical drugs.

• Ongoing commercialization efforts for new generic and licensed products in Canada.